Suzuki Hidenori, Ahuja Christopher S, Salewski Ryan P, Li Lijun, Satkunendrarajah Kajana, Nagoshi Narihito, Shibata Shinsuke, Fehlings Michael G
Division of Genetics and Development, Krembil Research Institute, Toronto, Canada.
Department of Orthopedics Surgery, Yamaguchi University Graduate School of Medicine, Ube, Japan.
PLoS One. 2017 Aug 3;12(8):e0182339. doi: 10.1371/journal.pone.0182339. eCollection 2017.
Traumatic spinal cord injuries (SCIs) affect millions of people worldwide; the majority of whom are in the chronic phase of their injury. Unfortunately, most current treatments target the acute/subacute injury phase as the microenvironment of chronically injured cord consists of a well-established glial scar with inhibitory chondroitin sulfate proteoglycans (CSPGs) which acts as a potent barrier to regeneration. It has been shown that CSPGs can be degraded in vivo by intrathecal Chondroitinase ABC (ChABC) to produce a more permissive environment for regeneration by endogenous cells or transplanted neural stem cells (NSCs) in the subacute phase of injury. Using a translationally-relevant clip-contusion model of cervical spinal cord injury in mice we sought to determine if ChABC pretreatment could modify the harsh chronic microenvironment to enhance subsequent regeneration by induced pluripotent stem cell-derived NSCs (iPS-NSC). Seven weeks after injury-during the chronic phase-we delivered ChABC by intrathecal osmotic pump for one week followed by intraparenchymal iPS-NSC transplant rostral and caudal to the injury epicenter. ChABC administration reduced chronic-injury scar and resulted in significantly improved iPSC-NSC survival with clear differentiation into all three neuroglial lineages. Neurons derived from transplanted cells also formed functional synapses with host circuits on patch clamp analysis. Furthermore, the combined treatment led to recovery in key functional muscle groups including forelimb grip strength and measures of forelimb/hindlimb locomotion assessed by Catwalk. This represents important proof-of-concept data that the chronically injured spinal cord can be 'unlocked' by ChABC pretreatment to produce a microenvironment conducive to regenerative iPS-NSC therapy.
创伤性脊髓损伤(SCI)影响着全球数百万人;其中大多数处于损伤的慢性期。不幸的是,目前大多数治疗针对的是急性/亚急性损伤期,因为慢性损伤脊髓的微环境由成熟的胶质瘢痕组成,其中含有抑制性硫酸软骨素蛋白聚糖(CSPG),它是再生的强大障碍。研究表明,在损伤的亚急性期,鞘内注射硫酸软骨素酶ABC(ChABC)可在体内降解CSPG,为内源性细胞或移植的神经干细胞(NSC)创造更有利于再生的环境。我们使用与转化相关的小鼠颈脊髓损伤夹伤模型,试图确定ChABC预处理是否可以改变恶劣的慢性微环境,以增强诱导多能干细胞衍生的神经干细胞(iPS-NSC)随后的再生能力。在损伤后7周的慢性期,我们通过鞘内渗透泵给予ChABC一周,然后在损伤中心的头侧和尾侧进行实质内iPS-NSC移植。给予ChABC减少了慢性损伤瘢痕,并显著提高了iPSC-NSC的存活率,且能清晰地分化为所有三种神经胶质谱系。在膜片钳分析中,移植细胞衍生的神经元也与宿主回路形成了功能性突触。此外,联合治疗使关键功能肌肉群恢复,包括前肢握力以及通过Catwalk评估的前肢/后肢运动指标。这代表了重要的概念验证数据,即慢性损伤的脊髓可以通过ChABC预处理“解锁”,以产生有利于再生性iPS-NSC治疗的微环境。